Establishment of New Senior Leadership Team
N4 Pharma establishes senior leadership team of four consultant experts to support Board in delivering strategic objectives.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the formation of a new Senior Leadership Team comprising leading expert consultants in drug development and research, commercial strategy, and pharmaceutical manufacturing.
The Senior Leadership Team will support the Board in delivering N4 Pharma's strategic and scientific objectives set out by the Company at the recent successful placing. The focus of the use of proceeds is to advance the development of Nuvec® as a novel delivery platform and build out the commercial data room in order to strengthen discussions with potential commercial partners.
The Senior Leadership Team, which reports to the Chief Executive Officer, comprises the following members:
Dr Fiona McLaughlin - Head of Research and Development
Mark Edbrooke - Head of Strategy
Dr Simon Bennett - Commercial Director
Dr Simon Bennett is an independent consultant with over 28 years of experience in the bio-pharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford.
Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC)
Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:
"The Senior Leadership Team that we have formed to help us swiftly deliver on our strategic and scientific goals is a world-class group of consultants with extensive experience in drug development, manufacturing and commercialisation. These appointments bring essential expertise to advance the Nuvec® platform towards our goal of commercial partnerships as well as build a pipeline of novel, highly valuable RNA therapeutic concepts for N4 Pharma to develop in-house.
"Each member of the Senior Leadership Team brings deep expertise and a proven track record in their respective fields. Their involvement with N4 Pharma on the development of Nuvec® is a strong endorsement of the progress to date and a clear demonstration of confidence in its future potential.
"The Board looks forward to their valuable guidance as we continue to unlock the full potential of Nuvec® as a novel delivery platform to enable advanced therapies for cancer and other diseases."
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Submit your questions directly to the management team via the N4 Pharma Investor Hub | Via N4 Pharma Investor Hub: investors.n4pharma.com https://investors.n4pharma.com/link/pegvRy |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896 |
About N4 Pharma
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.